表紙:リバーロキサバンの世界市場:規模、シェア、動向、予測(2022年~2028年)
市場調査レポート
商品コード
1084472

リバーロキサバンの世界市場:規模、シェア、動向、予測(2022年~2028年)

Rivaroxaban Market - Size, Share, Trends, and Forecast, 2022 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 150 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
リバーロキサバンの世界市場:規模、シェア、動向、予測(2022年~2028年)
出版日: 2022年05月24日
発行: Coherent Market Insights
ページ情報: 英文 150 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のリバーロキサバンの市場規模は、適応症拡大のための臨床試験の増加などによって促進されています。一方で、薬剤の副作用や代替療法が予測期間中の同市場の成長を抑制する可能性があります。

当レポートでは、世界のリバーロキサバン市場を調査しており、市場の概要、市場規模や予測、動向、成長要因、抑制要因、製品タイプ・用途・地域別の分析、および競合情勢などを提供しています。

目次

第1章 調査目的・前提条件

  • 調査目的
  • 仮定
  • 略語

第2章 市場概要

  • レポートの説明
  • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場内訳:製品タイプ別
    • 市場内訳:用途別
    • 市場内訳:流通チャネル別
    • 市場内訳:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、および動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 業界の動向
  • 規制シナリオ
  • 疫学

第4章 世界のリバーロキサバン市場:製品タイプ別(2017年~2028年)

  • イントロダクション
  • 10mg
  • 15mg
  • 20mg

第5章 世界のリバーロキサバン市場:用途別(2017年~2028年)

  • イントロダクション
  • 深部静脈血栓症の予防
  • 肺塞栓症

第6章 世界のリバーロキサバン市場:流通チャネル別(2017年~2028年)

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界のリバーロキサバン市場:地域別(2017年~2028年)

  • イントロダクション
  • 北米
  • 米国
  • カナダ
  • 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • 中国
  • 日本
  • インド
  • ASEAN
  • オーストラリア
  • 韓国
  • その他アジア太平洋
  • ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ
  • 中東
  • GCC諸国
  • イスラエル
  • その他中東
  • アフリカ
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ

第8章 競合情勢

  • ヒートマップ分析
  • 企業プロファイル
    • Janssen Pharmaceuticals Inc.*
    • Bayer AG
  • アナリストの見解

第9章 セクション

目次
Product Code: CMI1962

Rivaroxaban is an anti-coagulant medication marketed under the brand name Xarelto by Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. The report segments the rivaroxaban market based on strength of the drug, application, distribution channel, and region. The product is segmented into 10 mg, 15 mg, and 20 mg on the basis of strength and by application, it is segmented into deep venous thrombosis and pulmonary embolism. The report on rivaroxaban is intended to target the innovators and developers to provide in-depth analysis of the present market and the expected market scenario after the patent expiration. This report compiles the global rivaroxaban market overview, dynamics, opportunities, regional analysis, and market players.

Market Dynamics

Increasing clinical trials for the expansion of present indication of rivaroxaban is expected to be the key factor driving the rivaroxaban market growth over the forecast period. For instance, as per the data of clinical trials accessed on July 2018, Swiss Paraplegic Centre was evaluating rivaroxaban for cervical spinal cord injuries, with its successful entry in phase IV. The high cost of patented drug is a major factor contributing to high revenues and compound annual growth rate (CAGR). However, patent expiration of the drug in 2021 is expected to decrease the company revenues with the entry of new entrants with generic version of the drug at lower cost. The adverse effects of the drug such as risk of bleeding in patients leading to serious and fatal conditions are expected to restrain rivaroxaban market growth. Moreover, alternative therapies such as warfarin and heparin are cheaper, as compared to rivaroxaban and are expected to hamper growth of the global rivaroxaban market.

Key features of the study:

This report provides in-depth analysis of the rivaroxaban market and provides market size (US$ Million) and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global rivaroxaban market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Janssen Pharmaceuticals Inc. and Bayer AG

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics

The global rivaroxaban market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of rivaroxaban, research and consulting firms, new entrants, and financial analysts

Various strategy matrices used in analyzing the rivaroxaban market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

Global Rivaroxaban Market, By Strength:

10 mg

15 mg

20 mg

Global Rivaroxaban Market, By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

Global Rivaroxaban Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Rivaroxaban Market, By Region:

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Country:

U.S.

Canada

Latin America

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

Germany

U.K.

Italy

France

Spain

Russia

Rest of Europe

Asia Pacific

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

China

India

Japan

ASEAN

Australia

South Korea

Rest of Asia Pacific

Middle East

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

GCC

Israel

Rest of Middle East

Africa

By Strength:

10 mg

15 mg

20 mg

By Application:

Deep Vein Thrombosis Prophylaxis

Pulmonary Embolism

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By country:

North Africa

Central Africa

South Africa

Company Profiles

Janssen Pharmaceuticals Inc.*

Company Overview

Product Portfolio

Key Highlights

Financial Overview

Market Strategies

Bayer AG

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Strength
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Industry Trends
  • Regulatory Scenario
  • Epidemiology

4. Global Rivaroxaban Market, By Product Type, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • 10 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • 15 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • 20 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Rivaroxaban Market, By Application, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Deep Vein Thrombosis Prophylaxis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Pulmonary Embolism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Rivaroxaban Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Rivaroxaban Market, By Regions, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • U.S.
  • Canada
  • Europe
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Strength, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
  • Northern Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Janssen Pharmaceuticals Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategies
    • Bayer AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact